Yale Cancer Center

https://www.yalecancercenter.org/

 

GU
21:11

Yale Cancer Center

Tolerability of TKIs in aRCC Beyond 2L: Treatment Selection and Patient Evaluation

FEATURING Renee Maria Saliby
  • 24 views
  • December 19, 2024
09:57

Yale Cancer Center

Updates in Radioligand Therapies for Metastatic Prostate Cancer

FEATURING William Oh
  • 106 views
  • November 20, 2024
  • 1
21:43

Yale Cancer Center

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

FEATURING Isaac Kim
  • 464 views
  • September 23, 2024
  • 2
25:40

Yale Cancer Center

Molecular Markers of Microscopic Disease in RCC

FEATURING David Braun
  • 30 views
  • September 4, 2024
12:46

Insights from AUA 2024 Annual Meeting

AUA 2024 Insights: "Patterns of Chemotherapy Use With Primary RT for Localized Bladder Cancer - Analysis of the SEER Database"

FEATURING Fed Ghali
  • 108 views
  • May 21, 2024
09:59

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Determinants of Resistance to Nivo Monotherapy Investigated Through Genomic and Transcriptomic Analysis of RCC Tumors From the HCRN GU16-260 Study"

FEATURING David Braun
  • 70 views
  • July 12, 2023
17:48

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Combination Therapies Come of Age in Kidney Cancer"

FEATURING David Braun
  • 50 views
  • July 12, 2023
15:15

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Discussion of LBA4619, Phase 3 THOR Study - Results of Erdafitinib vs. Chemo in Advanced/Metastatic UC With Select FGFR Alterations (The Emerging Role of Targeted Therapy)"

FEATURING Daniel Petrylak
  • 89 views
  • July 1, 2023
01:46

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Randomized Double-Blind Phase 3 KEYNOTE-921 Study: Pembro + Docetaxel for Patients With mCRPC

FEATURING Daniel Petrylak
  • 281 views
  • February 28, 2023
  • 1
10:55

Yale Cancer Center

Systemic Therapies for Clear Cell RCC: Where Are We Now?

FEATURING David Braun
  • 468 views
  • December 23, 2022
  • 2
04:55

Yale Cancer Center

Post-Hoc Analyses of Phase 3 ARCHES Trial: OS in Patients With mHSPC Who Received Prior ADT and Reached Low PSA Levels Treated Further With Enzalutamide

FEATURING Daniel Petrylak
  • 665 views
  • December 16, 2022
  • 1
18:43

Yale Cancer Center

Smilow Shares with Primary Care: Prostate Cancer Screening Case 47 y/o Male With Family History of Prostate Cancer

FEATURING Erin Culbert
  • 267 views
  • September 19, 2022
07:51

Yale Cancer Center

Prostate Cancer Case Discussion: 57 y/o Asymptomatic Male With PSA of 5.6

FEATURING Gerald Portman
  • 84 views
  • September 19, 2022
10:09

Yale Cancer Center

Yale Cancer Center Radiation Therapy Updates for Prostate Cancer

FEATURING Bruce McGibbon
  • 227 views
  • September 19, 2022
  • 1
05:46

Yale Cancer Center

Prostate Cancer Case Discussion: 82 y/o Male With Gleason 9 Adenocarcinoma With Multiple Bone Mets

FEATURING Daniel Petrylak
  • 292 views
  • September 19, 2022
  • 1
12:24

Yale Cancer Center

2020 Highlights on Anti-Androgens in High-Risk PC: Does ADT+Abiraterone Combo Improve OS? How Does the Addition of Olaparib After Docetaxel Affect PFS?

FEATURING Daniel Petrylak
  • 22 views
  • September 27, 2020
13:36

Yale Cancer Center

What Are the Clinical Outcomes of Patients Treated With Local Therapies With Oligometastatic Renal Cell Carcinoma?

FEATURING Zhan Wu
  • 15 views
  • June 26, 2020
16:59

Yale Cancer Center

Prostatectomy vs. Radiation in Localized Prostate Cancer: Which Treatment Regimen Provides More Benefit?

FEATURING Bryan Kaps
  • 34 views
  • June 26, 2020
05:33

Yale Cancer Center

2020 ASCO Update on CPIs in mUC: What Are the FDA Approved CPIs? Should the Checkpoint Therapy Be Moved Up Earlier? Is There a Benefit of CPIs in Adjuvant Setting?

FEATURING Daniel Petrylak
  • 344 views
  • June 12, 2020
  • 2